Clinical Trial Update: R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial of R-CHOP plus alemtuzumab for chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: CABYC | Conditions: Chronic Lymphocytic Leukaemia, Patients Resistant to a Purine Analogous | Phase 2 | Status: WITHDRAWN